Table 7.
Association of PSRC1, CELSR2, and SORT1 SNPs with Warfarin Sensitivity During the Stabilization Phase of Therapy of 139 Cardiovascular Patients Treated with Warfarin
| Gene | SNP ID | Genotype | Sensitivea (n= 20) | Moderateb (n= 86) | Resistancec (n= 33) | Overall P-value* |
|---|---|---|---|---|---|---|
| PSRC1 | rs646776 | CC | (0/6) 0.0% | (4/6) 66.7% | (2/6) 33.3% | 0.031 |
| P-value* | 0.32 | 0.84 | 0.55 | |||
| CT | (13/48) 27.1% | (27/48) 56.3% | (8/48) 16.7% | |||
| P-value* | 0.002 | 0.32 | 0.16 | |||
| TT | (7/85) 8.2% | (55/85) 64.7% | (23/85) 27.1% | |||
| P-value* | 0.01 | 0.37 | 0.23 | |||
| CELSR2 | rs660240 | CC | (7/83) 8.4% | (52/83) 62.7% | (24/83) 28.9% | 0.038 |
| P-value* | 0.02 | 0.69 | 0.13 | |||
| TC | (12/46) 26.1% | (27/46) 58.7% | (7/46) 15.2% | |||
| P-value* | 0.004 | 0.62 | 0.07 | |||
| TT | (0/6) 0.0% | (4/6) 66.7% | (2/6) 33.3% | |||
| P-value* | 0.32 | 0.76 | 0.62 | |||
| rs12740374 | GG | (7/89) 7.9% | (58/89) 65.2% | (24/89) 27% | 0.026 | |
| P-value* | 0.01 | 0.37 | 0.27 | |||
| GT | (12/44) 27.3% | (25/44) 56.8% | (7/44) 15.9% | |||
| P-value* | 0.002 | 0.37 | 0.13 | |||
| TT | (0/5) 0.0% | (3/5) 60% | (2/5) 40% | |||
| P-value* | 0.37 | 0.92 | 0.37 | |||
| SORT1 | rs602633 | GG | (6/79) 7.6% | (52/79) 65.8% | (21/79) 26.6% | 0.071 |
| P-value* | 0.01 | 0.23 | 0.37 | |||
| GT | (13/50) 26% | (27/50) 54% | (10/50) 20% | |||
| P-value* | 0.004 | 0.16 | 0.42 | |||
| TT | (1/9) 11.1% | (6/9) 66.7% | (2/9) 22.2% | |||
| P-value* | 0.76 | 0.76 | 0.92 |
Notes: *Chi-square test with p< 0.05 is considered significant. aWarfarin sensitive group (required minimum warfarin dose < 21 mg/week). bWarfarin moderate response group (required average warfarin dose between 21 and 49 mg/week). cWarfarin resistance group (required high warfarin dose > 49 mg/week).